ClinicalTrials.gg
Not yet recruitingNCT07489755Updated Mar 24, 2026

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

A Phase 3 interventional study of TGRX-678 and TKI in Chronic Myelogenous Leukemia and Chronic Myelogenous Leukemia - Chronic Phase, sponsored by Shenzhen TargetRx Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Shenzhen TargetRx Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs

Read the detailed description

This Phase III study is of randomized, open-label and multi-center designs to study safety and efficacy profiles of TGRX-678 in CML-CP patients. Patients need to have medical history of failing treatment(s) from at least 3 TKI drugs. Patients with or without T315I mutation is enrolled. Patients are randomized to either TGRX-678 treatment or TKI treatment at investigator's decision.

02

Conditions studied

  • Chronic Myelogenous Leukemia
  • Chronic Myelogenous Leukemia - Chronic Phase
03

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's planned enrollment of 180 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Shenzhen TargetRx Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to consent and to follow study procedures
  • 18 years of age or above at time of screening; both sexes eligible
  • Diagnosed with CML-CP and was intolerant to or failed from at least 3 TKI treatments
  • score >= 2
  • Adequate hematological indicators and have not used blood products or Colony-Stimulating Factor (CSF)
  • Adequate kidney, liver and coagulation function
  • Adequate as confirmed by (ECG) test
  • Negative pregnancy result at screening for female patients of
  • Willing to take measure during the study (For male and female patients of child-bearing potential)

Exclusion criteria

Exclusion Criteria:

  • Reception of TKI treatment or other anti-tumor treatments prior to first dose
  • History or presence of extramedullary leukemia
  • History of progression to CML-AP or BP
  • Presence or having uncontrolled condition for cardiovascular diseases
  • History of severe hemorrhagic disease
  • Presence of malabsorption or other conditions that may affect drug absorption
  • History of other primary within 5 years
  • Presence of continuous or active infection (including , , )
  • In need for or having long-term immune suppressive treatment
  • Reception of major surgery 28 days before first dose
  • Presence of unrecovered toxicity due to anti-tumor treatment with grade >=1
  • Presence of other conditions that the investigators or medical monitor deem unfit for the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    TGRX-678

    Patients randomly assigned to this arm will take TGRX-678 as treatment for CML

    Drug: TGRX-678

  • Active comparator
    TKI

    Patients randomly assigned to this arm will take TKI of investigator's choice as treatment for CML

    Drug: TKI

Interventions

  • Patients will be given TGRX-678 for oral administration

  • DrugTKI

    Patient will take TKI of investigator's choice for oral administration

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    EFS measures time duration between randomization to disease progression, treatment failure, loss of efficacy, development of new mutation, or death, whichever occurs first

    Time frame: from randomization to occurance of any of the above-mentioned events (estimated study duration: 5 years)

Secondary outcomes

  1. Hematologic Response

    Rate of occurence of complete hematologic response (CHR).

    Time frame: From randomization to end of study (estimated study duration: 5 years)

  2. Cytogenetic Response

    Rate of occurence of Major Cytogenetic Response (MCyR) and Complete Cytogenetic Response (CCyR).

    Time frame: from randomization to end of study (estimated study duration: 5 years)

  3. Molecular Response

    Rate of Occurence for Major Molecular Response (MMR)

    Time frame: from randomization to end of study (estimated study duration: 5 years)

  4. Progression Free Survival (PFS)

    Duration between enrollment to progressive disease or death of any cause

    Time frame: from randomization to end of study (estimated study duration: 5 years)

  5. Overall Survival (OS)

    Duration between enrollment to death of any cause

    Time frame: from randomization to end of study (estimated study duration: 5 years)

  6. Treatment Emergent Adverse Event (TEAE)

    To record and analyse the occurence and frequency of adverse events during the study

    Time frame: from randomization to end of study (estimated study duration: 5 years)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for May 2030, 49 months later.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
May 1, 2030
CompletionEst.
May 1, 2031
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07489755
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
May 1, 2030 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Mar 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion